Compare BIVI & NVNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BIVI | NVNO |
|---|---|---|
| Founded | 2013 | 1987 |
| Country | United States | United States |
| Employees | N/A | 33 |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5M | 7.2M |
| IPO Year | 2013 | N/A |
| Metric | BIVI | NVNO |
|---|---|---|
| Price | $1.60 | $10.80 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 77.4K | 5.7K |
| Earning Date | 05-11-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $140.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.88 | $0.30 |
| 52 Week High | $9.09 | $13.44 |
| Indicator | BIVI | NVNO |
|---|---|---|
| Relative Strength Index (RSI) | 52.08 | 40.32 |
| Support Level | $1.45 | $9.78 |
| Resistance Level | $1.69 | $12.84 |
| Average True Range (ATR) | 0.12 | 0.77 |
| MACD | 0.00 | -0.25 |
| Stochastic Oscillator | 42.11 | 8.32 |
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
enVVeno Medical Corp is a medical device company focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The company first developed the VenoValve, which was a surgical replacement venous valve. It is focused on its next-generation, non-surgical venous valve product, called the enVVe System which consists of the enVVe Valve, enVVe Delivery System, enVVe Nose Cone, the enVVe Delivery System Accessories, and the enVVe Crimping System. The enVVe System is designed to treat severe deep chronic venous insufficiency through a minimally invasive, catheter-based approach. It operates in a single segment, Medical Device development, located in a single geographic location, the United States.